PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 162 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2019. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $563,380 | -29.0% | 214,213 | -4.7% | 0.00% | -50.0% |
| Q2 2023 | $793,519 | +47.7% | 224,793 | +29.3% | 0.00% | +100.0% |
| Q1 2023 | $537,091 | -60.5% | 173,816 | -45.9% | 0.00% | -66.7% |
| Q4 2022 | $1,358,917 | +12.6% | 321,257 | -19.1% | 0.00% | +50.0% |
| Q4 2021 | $1,207,000 | +640.5% | 396,967 | +1605.5% | 0.00% | +100.0% |
| Q3 2021 | $163,000 | -69.0% | 23,276 | +71.4% | 0.00% | -50.0% |
| Q1 2019 | $526,000 | +118.3% | 13,576 | +15.1% | 0.00% | 0.0% |
| Q4 2018 | $241,000 | -16.6% | 11,796 | +141.1% | 0.00% | -50.0% |
| Q2 2018 | $289,000 | -44.4% | 4,892 | -72.4% | 0.00% | -20.0% |
| Q1 2016 | $520,000 | -93.0% | 17,700 | -81.4% | 0.01% | -92.9% |
| Q4 2015 | $7,445,000 | +90.9% | 94,965 | +475.1% | 0.07% | +37.3% |
| Q1 2015 | $3,899,000 | +527.9% | 16,513 | +75.4% | 0.05% | +466.7% |
| Q2 2014 | $621,000 | – | 9,416 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
| Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
| Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
| Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
| GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
| Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
| GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
| Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
| ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |